Nurix Therapeutics CLO Christine Ring's Stock Transactions and Option Exercises

This Form 4 filing reports transactions by Christine Ring, Chief Legal Officer of Nurix Therapeutics, on June 25, 2026. Ring exercised two stock option grants: 13,333 shares at $7.26 per share and 15,602 shares at $8.72 per share, acquiring a total of 28,935 shares. She then sold 28,935 shares at a weighted average price of $20.0624 per share, resulting in net proceeds. Following these transactions, Ring holds 13,579 common shares directly and retains 134,398 stock options. All transactions were executed pursuant to a Rule 10b5-1 trading plan, indicating pre-planned, non-discretionary trades. The options had different vesting schedules, with one fully vested by January 2024 and the other vesting monthly through February 2027.